Advances in Therapeutic Cancer Vaccines: Harnessing Immune Adjuvants for Enhanced Efficacy and Future Perspectives

Overview

Journal Comput Struct Biotechnol J

Specialty Biotechnology

Date 2024 May 6

PMID 38707540

Authors

Dekang Ren

Shizheng Xiong

Yujie Ren

Xueni Yang

Xinmiao Zhao

Jiaming Jin

Miaomiao Xu

Tingming Liang

Li Guo

Lixing Weng

Affiliations

Soon will be listed here.

Abstract

Preventive cancer vaccines are highly effective in preventing viral infection-induced cancer, but advances in therapeutic cancer vaccines with a focus on eliminating cancer cells through immunotherapy are limited. To develop therapeutic cancer vaccines, the integration of optimal adjuvants is a potential strategy to enhance or complement existing therapeutic approaches. However, conventional adjuvants do not satisfy the criteria of clinical trials for therapeutic cancer vaccines. To improve the effects of adjuvants in therapeutic cancer vaccines, effective vaccination strategies must be formulated and novel adjuvants must be identified. This review offers an overview of the current advancements in therapeutic cancer vaccines and highlights in situ vaccination approaches that can be synergistically combined with other immunotherapies by harnessing the adjuvant effects. Additionally, the refinement of adjuvant systems using cutting-edge technologies and the elucidation of molecular mechanisms underlying immunogenic cell death to facilitate the development of innovative adjuvants have been discussed.

Citing Articles

Nanomedicines harnessing cGAS-STING pathway: sparking immune revitalization to transform 'cold' tumors into 'hot' tumors.

Ying X, Chen Q, Yang Y, Wu Z, Zeng W, Miao C Mol Cancer. 2024; 23(1):277.

PMID: 39710707 PMC: 11664935. DOI: 10.1186/s12943-024-02186-6.

References

Larkin H . Novavax COVID-19 Vaccine Booster Authorized. JAMA. 2022; 328(21):2101. DOI: 10.1001/jama.2022.20028. View

Franceschi S . Strategies to reduce the risk of virus-related cancers. Ann Oncol. 2000; 11(9):1091-6. DOI: 10.1023/a:1008344502623. View

Potluri H, Ng T, Newton M, McNeel D . GM-CSF elicits antibodies to tumor-associated proteins when used as a prostate cancer vaccine adjuvant. Cancer Immunol Immunother. 2022; 71(9):2267-2275. PMC: 9744072. DOI: 10.1007/s00262-022-03150-3. View

Sahin U, Oehm P, Derhovanessian E, Jabulowsky R, Vormehr M, Gold M . An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma. Nature. 2020; 585(7823):107-112. DOI: 10.1038/s41586-020-2537-9. View

Banki Z, Posch W, Ejaz A, Oberhauser V, Willey S, Gassner C . Complement as an endogenous adjuvant for dendritic cell-mediated induction of retrovirus-specific CTLs. PLoS Pathog. 2010; 6(4):e1000891. PMC: 2861708. DOI: 10.1371/journal.ppat.1000891. View

Pollack K, Meneveau M, Melssen M, Lynch K, Koeppel A, Young S . Incomplete Freund's adjuvant reduces arginase and enhances Th1 dominance, TLR signaling and CD40 ligand expression in the vaccine site microenvironment. J Immunother Cancer. 2020; 8(1). PMC: 7213888. DOI: 10.1136/jitc-2020-000544. View

Zhou W, Zhou Y, Chen X, Ning T, Chen H, Guo Q . Pancreatic cancer-targeting exosomes for enhancing immunotherapy and reprogramming tumor microenvironment. Biomaterials. 2020; 268:120546. DOI: 10.1016/j.biomaterials.2020.120546. View

Melo A, Macedo L, Invencao M, Moura I, da Gama M, de Melo C . Third-Generation Vaccines: Features of Nucleic Acid Vaccines and Strategies to Improve Their Efficiency. Genes (Basel). 2022; 13(12). PMC: 9777941. DOI: 10.3390/genes13122287. View

Hu Z, Ott P, Wu C . Towards personalized, tumour-specific, therapeutic vaccines for cancer. Nat Rev Immunol. 2017; 18(3):168-182. PMC: 6508552. DOI: 10.1038/nri.2017.131. View

10.

Hammerich L, Marron T, Upadhyay R, Svensson-Arvelund J, Dhainaut M, Hussein S . Systemic clinical tumor regressions and potentiation of PD1 blockade with in situ vaccination. Nat Med. 2019; 25(5):814-824. DOI: 10.1038/s41591-019-0410-x. View

11.

Gujar S, Lee P . Oncolytic virus-mediated reversal of impaired tumor antigen presentation. Front Oncol. 2014; 4:77. PMC: 3989761. DOI: 10.3389/fonc.2014.00077. View

12.

Abbas A, Trotta E, Simeonov D, Marson A, Bluestone J . Revisiting IL-2: Biology and therapeutic prospects. Sci Immunol. 2018; 3(25). DOI: 10.1126/sciimmunol.aat1482. View

13.

Yan H, Lin G, Liu Z, Gu F, Zhang Y . Nano-adjuvants and immune agonists promote antitumor immunity of peptide amphiphiles. Acta Biomater. 2023; 161:213-225. DOI: 10.1016/j.actbio.2023.02.034. View

14.

Hanggi K, Ruffell B . Cell death, therapeutics, and the immune response in cancer. Trends Cancer. 2023; 9(5):381-396. PMC: 10121860. DOI: 10.1016/j.trecan.2023.02.001. View

15.

Jin W, Jagodinsky J, Vera J, Clark P, Zuleger C, Erbe A . NK cells propagate T cell immunity following in situ tumor vaccination. Cell Rep. 2023; 42(12):113556. PMC: 10843551. DOI: 10.1016/j.celrep.2023.113556. View

16.

Wang Q, Ju X, Wang J, Fan Y, Ren M, Zhang H . Immunogenic cell death in anticancer chemotherapy and its impact on clinical studies. Cancer Lett. 2018; 438:17-23. DOI: 10.1016/j.canlet.2018.08.028. View

17.

Sun H, Hu W, Yan Y, Zhang Z, Chen Y, Yao X . Using PAMPs and DAMPs as adjuvants in cancer vaccines. Hum Vaccin Immunother. 2021; 17(12):5546-5557. PMC: 8903972. DOI: 10.1080/21645515.2021.1964316. View

18.

Palucka K, Banchereau J . Cancer immunotherapy via dendritic cells. Nat Rev Cancer. 2012; 12(4):265-77. PMC: 3433802. DOI: 10.1038/nrc3258. View

19.

Blass E, Ott P . Advances in the development of personalized neoantigen-based therapeutic cancer vaccines. Nat Rev Clin Oncol. 2021; 18(4):215-229. PMC: 7816749. DOI: 10.1038/s41571-020-00460-2. View

20.

Hwang H, Cherukula K, Bang Y, Vijayan V, Moon M, Thiruppathi J . Combination of Photodynamic Therapy and a Flagellin-Adjuvanted Cancer Vaccine Potentiated the Anti-PD-1-Mediated Melanoma Suppression. Cells. 2020; 9(11). PMC: 7694978. DOI: 10.3390/cells9112432. View